Dec 12, 2022 | Press Releases
Financing transactions include approximately $50 million of equity financing from a single institutional investor, $50 million of debt financing from Nant Capital, LLC, and conversion of approximately $56.6 million of debt held by NantWorks LLC into ImmunityBio...
Nov 17, 2022 | Press Releases
CULVER CITY, Calif., November 17, 2022 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City,...
Nov 10, 2022 | Press Releases
Primary endpoint met in high-risk carcinoma in situ (CIS) cohort with 71% complete response rate (CR) with a median duration of response of 26.6 months, a 53% CR rate at 24 months and a safety profile comparable to BCG alone This novel IL-15 superagonist N-803 –...
Oct 27, 2022 | Press Releases
CULVER CITY, Calif.-Oct. 27, 2022– ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be presenting at the Jefferies London Healthcare Conference, which is taking place in London from November 15-17,...
Jul 28, 2022 | Press Releases
This acceptance represents the first regulatory filing for N-803, an IL-15 superagonist, which was granted Breakthrough Therapy and Fast Track designations in combination with Bacillus Calmette-Guérin (BCG) from the U.S. Food and Drug Administration (FDA) for this...
Jun 6, 2022 | Press Releases
Data from trials underscore ImmunityBio’s vision of activating NK cells and T cells to advance care in difficult-to-treat cancers Bladder Cancer: 71% of BCG-unresponsive NMIBC patients who had failed on previous therapies showed a complete response with a median...